Marc Evanchik
About Marc Evanchik
Marc Evanchik Vice President at Edgewise
Marc Evanchik holds the position of Vice President, Discovery and Translational Pharmacology at Edgewise. In this role, he is integral to the company's mission of discovering and developing new treatment options. His position emphasizes the importance of translating scientific research into practical therapies aimed at addressing unmet medical needs.
Discovery and Translational Pharmacology at Edgewise
As Vice President of Discovery and Translational Pharmacology, Marc Evanchik focuses on advancing scientific discoveries through to clinical applications. This involves overseeing the processes that convert basic research findings into viable treatment options, particularly for muscular dystrophies like Duchenne and Becker. His role is crucial in bridging the gap between laboratory research and patient care.
Marc Evanchik's Work with Duchenne and Becker Muscular Dystrophy
Marc Evanchik is passionate about addressing the needs of patients suffering from Duchenne and Becker muscular dystrophy. These conditions currently have limited treatment options, which makes his work critically important. At Edgewise, Evanchik is part of a dedicated team striving to bring novel and effective treatments to these underserved communities, underscoring his commitment to impactful scientific work.
Marc Evanchik's Commitment to Science and Patient Care
Marc Evanchik prides himself on working for Edgewise, where the alignment of good science with urgent patient needs is a core principle. His dedication is evident in his active involvement in the research and development of innovative treatments for muscular dystrophy. This dual focus on scientific integrity and patient impact defines his professional ethos at Edgewise.